astrazeneca glp 1 Readout Newsletter: Abeona, Pfizer, Regeneron, AstraZeneca Moves Toward the Oral

These subtype-specific findings reinforce the mechanistic rationale for GLP-1 agonists in neuroprotection, Wu said

The severity and duration of nausea often depend on the dose, rate of titration, and individual patient factors such as baseline gastrointestinal sensitivity

Instead, clinicians should acknowledge this risk and consider individualized risk-benefit strategies when prescribing GLP-1 RAs, particularly for patients with pre-existing ocular manifestations and must inform patients regarding possible ocular hazards while advocating for regular retinal examinations and assessments of visual acuity

J Am Coll Cardiol (2014) 63:29853023

[DOI] [PMC free article] [PubMed] [Google Scholar] 79.Lu C-X, An X-X, Yu Y, Jiao L-R, Canarutto D, Li G-F, et al

10.1007/s13300-012-0013-8